Making an Impact in homes, in the field, in the lab, around the world
Through KUCTC, businesses and investors have access to leading edge research and more than 100 technologies to fuel the next-generation of products, services and health care. We invite you to explore the impact stories below and browse our technology database.
Truvada (emtricitabine, tenofovir disoproxil fumarate)
Atripla (efavirenz, emtricitabine, tenofovir disoproxil fumarate)
Complera (rilivirine, emtricitabine, tenofovir disoproxil fumarate)
Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate)
Truvada (emtricitabine, tenofovir disoproxil fumarate): HIV prevention
Viread (tenofovir disoproxil fumarate): Hepatitis B
Noxafil (posaconazole, Captisol): Aspergillus, Candida
Kyprolis (carfilzomib, Captisol)
Evomela (melphalan, Captisol)
Geodon IM (ziprasidone, Captisol)
Procedural Sedation: Luseda (fospropofol)
Captisol® is a patent-protected, uniquely modified cyclodextrin developed by KU researchers. The chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. Ligand Pharmaceuticals has license rights to Captisol® and has partnerships for 34 Captisol® -enabled injectable products in clinical development. To learn more, visit ligand.com.
KU Success Stories
Not all KU technology is as big a commercial success as Abilify®, but it’s a great example of how innovation, research and protecting intellectual property are helping society and funding further research at KU. Click here to see more of KU's success stories.
KU Technologies Impact Lives
View the Lawrence Journal World Article: "‘It’s the impact you have on people’s lives’: Retiring KU professor invented widely used drugs for HIV and other conditions - Val Stella taught at KU 43 years".
View the video at BioNexus KC called, "Expert Exchange - Dr. Steven Soper - Tool for Cancer Diagnosis Aimed at Improving Patient Care"